Dianthus therapeutics, inc.DNTH.US Overview

US StockHealthcare

(No presentation for DNTH)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

DNTH Overall Performance

DNTH AI Analysis & Strategy

DNTH Recent Performance

-0.25%

Dianthus therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

DNTH PowerScanner

DNTH Key Information

DNTH Valuation Metrics

DNTH Earnings Table

DNTH Profile

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.